Alterity Therapeutics Advances Lead Drug Towards Pivotal Study For Rare Neuromuscular Disorder

Alterity Therapeutics Limited (NASDAQ:ATHE) stock is up during Tuesday’s session as the biotechnology company announced an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding its pivotal Phase 3 program for ATH434 in treating Multiple System Atrophy (MSA).

The FDA agreed on key elements of the proposed Phase 3 trial design, including the study population and dosing regimen, following ATH434’s demonstration of a 48% slowing of disease progression compared to placebo in the Phase 2 study.

The pivotal Phase 3 trial activities are on track to initiate by year-end 2026.

“The successful outcome of the meeting is an important de-risking milestone and gives us confidence as we finalize the protocol and prepare to initiate trial activities by year-end 2026… I am confident that ATH434 is well-positioned to become a disease-modifying therapy for individuals living with MSA,” said David Stamler, CEO of Alterity Therapeutics.

Phase 2 Data Continued To Support ATH434 Development

In April, Alterity Therapeutics presented new data analyses from the Phase 2 trial of ATH434, demonstrating clinical efficacy in MSA patients.

ATH434-201 trial showed meaningful results utilizing MuSyCA demonstrated robust sensitivity to disease progression, with placebo participants worsening by approximately +9.7 points over 52 weeks.

Consistent with prior data, ATH434 slowed disease progression on the MuSyCA assessment.

The company received positive regulatory feedback following an FDA Type C Meeting in April regarding its planned Phase 3 development program for ATH434.

Alterity received written feedback supporting its plans related to the chemistry, manufacturing, and control (CMC) elements of the program.

The first Type C Meeting in March was related to clinical pharmacology and non-clinical development aspects of the program.

How ATHE Ranks On Momentum Versus The Market

Below is the Benzinga Edge scorecard for Alterity Therapeutics, highlighting its strengths and weaknesses compared to the broader market:

Momentum: Weak (Score: 42.44) — Stock is underperforming the broader market.

ATHE Stock Price Activity: Alterity Therapeutics shares were up 24.62% at $4.88 at the time of publication on Tuesday, according to Benzinga Pro data.

Photo: Shutterstock